Welcome to
Madrigal Medical Affairs

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction steatohepatitis (MASH/NASH).

Metabolic Dysfunction Steatohepatitis (MASH/NASH)
Clinical Trials
Publications
Request Medical Information
Investigator-Initiated Studies

Welcome to Madrigal Medical Affairs

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction steatohepatitis (MASH/NASH).

Metabolic Dysfunction Steatohepatitis (MASH/NASH)
Clinical Trials
Publications
Request Medical Information
Submit an Educational Grant Request
Investigator-Initiated Studies

Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction Steatohepatitis (MASH/NASH)

Nonalcoholic Steatohepatitis (NASH)

Metabolic Dysfunction Steatohepatitis (MASH/NASH)

A Chronic Liver Disease

MASH/NASH* is a leading cause of liver-related mortality and an increasing burden on global healthcare systems.

*The nomenclature is transitioning from NASH (nonalcoholic steatohepatitis) to MASH (metabolic dysfunction steatohepatitis) and NAFLD (nonalcoholic fatty liver disease) to MASLD (metabolic associated liver disease)

A Chronic Liver Disease

MASH/NASH* is a leading cause of liver-related mortality and an increasing burden on global healthcare systems.

*The nomenclature is transitioning from NASH (nonalcoholic steatohepatitis) to MASH (metabolic dysfunction steatohepatitis) and NAFLD (nonalcoholic fatty liver disease) to MASLD (metabolic associated liver disease)

MASH/NASH Disease Information

The Role of Thyroid Hormone Receptor β (THR-β) in MASH/NASH

In MASH/NASH, reduced signaling via THR-β exacerbates hepatic mitochondrial dysfunction, inflammation, and fibrosis.

The Role of Thyroid Hormone Receptor β (THR-β) in NASH
The Role of Thyroid Hormone Receptor β (THR-β) in NASH

The Role of Thyroid Hormone Receptor β (THR-β) in NASH

In MASH/NASH, reduced signaling via THR-β exacerbates hepatic mitochondrial dysfunction, inflammation, and fibrosis.

Learn More About MASH/NASH

Our Research

Our Research

MAESTRO Clinical Development Program

Our clinical development program focuses on a thyroid hormone receptor-β (THR-β) agonist being studied for the treatment of MASH/NASH.

MAESTRO Clinical Development Program

Our clinical development program focuses on a thyroid hormone receptor-β (THR-β) agonist being studied for the treatment of MASH/NASH.

Publications

View key resmetirom and clinical publications along with recent congress presentations.

Phase 3 MAESTRO Clinical Program Publications
Phase 3 MAESTRO Clinical Program Publications

Publications

View key resmetirom and clinical publications along with recent congress presentations.

Request Medical Information

Request Medical Information

Request Information From the Madrigal Medical Information Team 

Submit an Educational Grant Request

Submit an Educational Grant Request

Submit an Educational Grant Request 

Investigator-Initiated Studies

Investigator-Initiated Studies

Learn more and submit a proposal 

Contact Us

Contact Us

Contact Us 

Resmetirom is currently only approved in the United States.